Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,689 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Men Clear all
Completed Phase 3 Interventional

Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer

NCT00028574
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
gabapentin, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
170
States / cities
Mobile, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 103 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 22, 2026, 11:21 PM EDT
Enrolling by invitation Not applicable Interventional

Mediterranean Diet Intervention Among Men at LBJ Hospital With Prostate Cancer

NCT06935097
View directory record Official record
Conditions
Prostate Cancer
Interventions
Mediterranean diet-based Intervention
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Not applicable Interventional

Cut Your Blood Pressure 3

NCT03726710
View directory record Official record
Conditions
Hypertension, High Blood Pressure, African American Men
Interventions
Blood Pressure measurement and pharmacy
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 79 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 22, 2026, 11:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predicting Peripheral Arterial Disease in Men With Erectile Dysfunction

NCT00743613
View directory record Official record
Conditions
Erectile Dysfunction, Peripheral Arterial Disease
Interventions
Sexual Health Inventory for Men (SHIM), Ankle-Brachial Index (ABI)
Behavioral · Procedure
Lead sponsor
Bruton Avenue Family Practice
Other
Eligibility
50 Years and older · Male only
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
5
States / cities
Fitchburg, Massachusetts • Hampton, Virginia • Newport News, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2008 · Synced Oct 22, 2026, 11:21 PM EDT
Recruiting Phase 1 Interventional

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

NCT07218913
View directory record Official record
Conditions
Hearing Loss, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Nongerminomatous Germ Cell Tumor, Metastatic Malignant Testicular Non-Seminomatous Germ Cell Tumor, Metastatic Testicular Seminoma, Stage II Testicular Cancer AJCC v8, Stage III Testicular Cancer AJCC v8
Interventions
Audiometric Test, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Sodium Thiosulfate Anhydrous
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

NCT03617081
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
NNC0113-2023, Placebo (NNC0113-2023)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.

NCT01293487
View directory record Official record
Conditions
Osteopenia, Osteoporosis, Bone Disease
Interventions
RN564
Biological
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
8
States / cities
Coral Gables, Florida • Miami, Florida • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 22, 2026, 11:21 PM EDT
Not yet recruiting Not applicable Interventional

Piloting FUERTE: Federally qUalified Health Centers Engaging Hispanic Men at Risk of diabeTEs

NCT07878806
View directory record Official record
Conditions
Prediabetes
Interventions
FUERTE Arm, Standard care, No Intervention
Behavioral · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 11:21 PM EDT
Terminated Phase 2 Interventional

Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer

NCT02459912
View directory record Official record
Conditions
Prostate Cancer
Interventions
Unilateral Nerve-Sparing Cryoablation of the Prostate, Precise Cryoablation System with IceRod Needles
Procedure · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 69 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Peer Genetic Study

NCT05011799
View directory record Official record
Conditions
Healthy Subject, Prostate Carcinoma
Interventions
Cancer Educational Materials, Questionnaire Administration, Educational Intervention
Behavioral · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
35 Years to 69 Years · Male only
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 22, 2026, 11:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Peak Impact Forces and Metabolic Cost During Mid-Forefoot Striking in Shod Versus Barefoot Runners

NCT01536171
View directory record Official record
Conditions
Healthy
Interventions
running with normal running shoes and barefoot
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Phase 2 Interventional Results available

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

NCT01750398
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Testosterone cypionate, Goserelin, Leuprolide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Phase 1 Interventional

Smoking Cessation and Sexual Health in Men

NCT00833404
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine transdermal patch
Drug
Lead sponsor
University of Texas at Austin
Other
Eligibility
23 Years to 60 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phlebotomy Study of Testosterone Undecanoate

NCT02670343
View directory record Official record
Conditions
Hypogonadism
Interventions
Oral Testosterone Undecanoate
Drug
Lead sponsor
Clarus Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 22, 2026, 11:21 PM EDT
Withdrawn Not applicable Interventional

Health Interventions in Men Undergoing Radical Prostatectomy

NCT01748110
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Urinary Incontinence
Interventions
Intensive Fitness Intervention, TRIMM
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Phase 1 Interventional

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

NCT02458716
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Prostate Carcinoma Metastatic to the Bone
Interventions
Robotic Assisted Radical Prostatectomy, Conventional open retropubic radical prostectomy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
Procedure · Other · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
3
States / cities
Duarte, California • Orange, California • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 22, 2026, 11:21 PM EDT
Withdrawn Phase 3 Interventional

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer

NCT01214291
View directory record Official record
Conditions
Risk of Bone Fracture Occurrences
Interventions
Toremifene
Drug
Lead sponsor
GTx
Industry
Eligibility
50 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Phase 2 Interventional Results available

A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

NCT01981122
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
sipuleucel-T, enzalutamide
Biological · Drug
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Providing Unique Support for Health (PUSH) Study

NCT03194477
View directory record Official record
Conditions
HIV-1-infection
Interventions
Mobile-enhanced Engagement Intervention
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
15 Years to 24 Years
Enrollment
631 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 22, 2026, 11:21 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

NCT05081193
View directory record Official record
Conditions
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone Undecanoate, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

T Cell Responses to Various Levels of Exercise Stress

NCT06638684
View directory record Official record
Conditions
Healthy
Interventions
Exercise
Other
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lawrence, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplementation With a Black Pepper Extract

NCT05199012
View directory record Official record
Conditions
Waist Circumference, Triglycerides, Appetite, Inflammation, Lipids
Interventions
Black pepper extract
Dietary Supplement
Lead sponsor
The Center for Applied Health Sciences, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 22, 2026, 11:21 PM EDT
Terminated Phase 2 Interventional Results available

Cabozantinib in Men With Castration-Resistant Prostate Cancer

NCT01703065
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 22, 2026, 11:21 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

NCT02854436
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Niraparib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Riverside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 22, 2026, 11:21 PM EDT